OmniaBio is redefining the future of cell therapy manufacturing through its proprietary AI-powered Intelligent Factory™. Purpose-built to accelerate discoveries and industrialize production, the Intelligent Factory™ integrates artificial intelligence and automation across the entire manufacturing lifecycle. With a focus on autologous CAR-T and other advanced therapies, OmniaBio’s platform enables scalable, efficient, and high-fidelity production by embedding predictive analytics, robotic bioprocessing, and digital quality systems into a unified, closed-loop system. This approach not only enhances throughput and consistency but also positions OmniaBio as a next-generation CDMO partner for innovators seeking to bring life-saving therapies to patients faster.
| Website | https://www.omniabio.com |
| Revenue | $63.4 million |
| Employees | 177 (128 on RocketReach) |
| Founded | 2022 |
| Address | 190 Longwood Rd S, Hamilton, Ontario L8P 0A6, CA |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Gene Therapy Manufacturing, Cell Therapy Manufacturing, Cell And Gene Therapy, Viral Vector Production, Cell Line Development, Advanced Therapy Medicinal Products, Phase 1 Clinical Trials, Contract Development Manufacturing, Bioprocessing, Cdmo Services, Biopharmaceutical Manufacturing, Pharmaceutical Development, Drug Manufacturing |
| Competitors | Amgen, AstraZeneca, Novartis, Gilead Sciences, Genentech, Regeneron, CureVac, Moderna Therapeutics, Sangamo Therapeutics, Inc., Agenus +40 more (view full list) |
Looking for a particular OmniaBio employee's phone or email?
The OmniaBio annual revenue was $63.4 million in 2026.
Jason Cervi is the CFO of OmniaBio.
128 people are employed at OmniaBio.
OmniaBio is based in Hamilton, Ontario.